'''Casokefamide''' ([[International Nonproprietary Name|INN]]), also known as '''β-casomorphin 4027''' ('''β-CM-4027''') and '''[<small>D</small>-Ala<sup>2,4</sup>,Tyr<sup>5</sup>]-β-casomorphin-5-amide''', is a [[peripheral|peripherally-specific]], [[Chemical synthesis|synthetic]] [[opioid peptide|opioid pentapeptide]] with the [[amino acid sequence]] Tyr-<small>D</small>-Ala-Phe-<small>D</small>-Ala-Tyr-NH<sub>2</sub>.<ref name="pmid8466524">{{cite journal |vauthors=Brantl V, Picone D, Amodeo P, Temussi PA | title = Solution structure of casokefamide | journal = Biochemical and Biophysical Research Communications | volume = 191 | issue = 3 | pages = 853–9 |date=March 1993 | pmid = 8466524 | doi = 10.1006/bbrc.1993.1295 | url = http://www.sciencedirect.com/science/article/pii/S0006291X83712957}}</ref> Derived from the [[β-casomorphin]] sequence, it was designed with the intention of improving resistance to [[digestive enzyme]]s so that it could be used as an [[antidiarrheal]] [[drug|medicine]].<ref name="pmid8466524" /><ref name="pmid10793229">{{cite journal |vauthors=Schulte-Frohlinde E, Reindl W, Bierling D | title = Effects of oral casokefamide on plasma levels, tolerance, and intestinal transit in man | journal = Peptides | volume = 21 | issue = 3 | pages = 439–42 |date=March 2000 | pmid = 10793229 | doi = 10.1016/S0196-9781(00)00166-2| url = http://www.sciencedirect.com/science/article/pii/S0196978100001662|display-authors=etal}}</ref> Unlike other casomorphins, which are generally [[binding selectivity|selective]] [[μ-opioid receptor]] [[agonist]]s, casokefamide binds to both the μ- and [[δ-opioid receptor]]s.<ref name="pmid8466524" /> In a [[clinical study]], casokefamide was found to be effective via the oral route for the treatment of chronic [[diarrhea]], and did not produce any [[side effect]]s.<ref name="pmid10793229" /> However, further clinical development was not pursued and it was never marketed.
